Pharmacological Treatments in Heart Failure With Mildly Reduced and Preserved Ejection Fraction

射血分数 心力衰竭 地高辛 医学 内科学 心脏病学 安慰剂 缬沙坦 射血分数保留的心力衰竭 血压 病理 替代医学
作者
Stefanos Zafeiropoulos,Ioannis T. Farmakis,Ioannis Milioglou,Ioannis Doundoulakis,Eiran Z. Gorodeski,Stavros Konstantinides,Lauren Cooper,Stavros Zanos,Stavros Stavrakis,Grigorios Giamouzis,Javed Butler,George Giannakoulas
出处
期刊:Jacc-Heart Failure [Elsevier]
卷期号:12 (4): 616-627 被引量:5
标识
DOI:10.1016/j.jchf.2023.07.014
摘要

Medical treatment for heart failure with preserved ejection (HFpEF) and heart failure with mildly reduced ejection fraction (HFmrEF) has weaker evidence compared with reduced ejection fraction, despite recent trials with an angiotensin receptor neprilysin inhibitor (ARNI) and sodium glucose co-transporter 2 inhibitors (SGLT2is). The authors aimed to estimate the aggregate therapeutic benefit of drugs for HFmrEF and HFpEF. The authors performed a systematic review of MEDLINE, CENTRAL, and Web of Science for randomized trials including patients with heart failure (HF) and left ventricular ejection fraction (LVEF) >40%, treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (analyzed together as renin-angiotensin system inhibitors [RASi]), beta-blockers (BBs), mineralocorticoid receptor antagonists (MRAs), digoxin, ARNI, and SGLT2i. An additive component network meta-analysis was performed. The primary outcome was a composite of cardiovascular (CV) death and first hospitalization for heart failure (HHF); secondary outcomes were CV death, total HHF, and all-cause mortality. The authors identified 13 studies with a total of 29,875 patients and a mean LVEF of 56.3% ± 8.7%. ARNI, MRA, and SGLT2i separately, but not RASi, BB, or digoxin, reduced the primary composite outcome compared with placebo. The combination of ARNI, BB, MRA, and SGLT2i was the most effective (HR: 0.47 [95% CI: 0.31-0.70]); this was largely explained by the triple combination of ARNI, MRA, and SGLT2i (HR: 0.56 [95% CI 0.43-0.71]). Results were similar for CV death (HR: 0.63 [95% CI 0.43-0.91] for ARNI, MRA, and SGLT2i) or total HHF (HR: 0.49 [95% CI 0.33-0.71] for ARNI, MRA, and SGLT2i) alone. In a subgroup analysis, only SGLT2i had a consistent benefit among all LVEF subgroups, whereas the triple combination had the greatest benefit in HFmrEF, robust benefit in patients with LVEF 50% to 59%, and a statistically marginal benefit in patients with LVEF ≥60%. In patients with HF and LVEF>40%, the quadruple combination of ARNI, BB, MRA, and SGLT2i provides the largest reduction in the risk of CV death and HHF; driven by the robust effect of the triple combination of ARNI, MRA, and SGLT2i. The benefit was more pronounced in HFmrEF patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
orixero应助顺利的柠檬采纳,获得10
刚刚
frank发布了新的文献求助10
1秒前
充电宝应助meimei采纳,获得10
1秒前
科研通AI2S应助lily采纳,获得10
1秒前
科研通AI2S应助紧张的怜寒采纳,获得10
1秒前
1秒前
2秒前
2秒前
陈乐宁2024发布了新的文献求助10
2秒前
巴纳拉发布了新的文献求助10
2秒前
贝熠呀完成签到,获得积分10
2秒前
大模型应助xinxinfenghuo采纳,获得10
2秒前
潘善若发布了新的文献求助10
3秒前
每天都要哈哈哈完成签到,获得积分10
4秒前
4秒前
百里如雪完成签到,获得积分10
5秒前
zzz发布了新的文献求助10
7秒前
小马甲应助贝熠呀采纳,获得10
7秒前
充电宝应助frank采纳,获得10
7秒前
乐乐应助kk采纳,获得30
8秒前
8秒前
xd发布了新的文献求助10
8秒前
Wu发布了新的文献求助10
8秒前
8秒前
雷7967发布了新的文献求助10
9秒前
9秒前
江柚白发布了新的文献求助10
9秒前
10秒前
光亮丹琴完成签到,获得积分10
10秒前
scott910806发布了新的文献求助10
11秒前
11秒前
King完成签到,获得积分10
11秒前
Lewis发布了新的文献求助10
11秒前
11秒前
LMAaonChen完成签到,获得积分10
11秒前
12秒前
潘善若完成签到,获得积分10
12秒前
发财糕发布了新的文献求助10
12秒前
12秒前
阿啵呲嘚呃of咯完成签到 ,获得积分10
13秒前
高分求助中
Sustainability in Tides Chemistry 2000
Microlepidoptera Palaearctica, Volumes 1 and 3 - 13 (12-Volume Set) [German] 1122
Дружба 友好报 (1957-1958) 1000
The Data Economy: Tools and Applications 1000
A Dissection Guide & Atlas to the Rabbit 600
中国心血管健康与疾病报告2023(要完整的报告) 500
Ожившие листья и блуждающие цветы. Практическое руководство по содержанию богомолов [Alive leaves and wandering flowers. A practical guide for keeping praying mantises] 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3101982
求助须知:如何正确求助?哪些是违规求助? 2753257
关于积分的说明 7623194
捐赠科研通 2405938
什么是DOI,文献DOI怎么找? 1276507
科研通“疑难数据库(出版商)”最低求助积分说明 616864
版权声明 599076